恶性黑色素瘤患者EORTC QLQ-C30最小重要差异的解读
该研究汇总三项已发表的黑色素瘤III期试验数据,以临床医生评分为锚,采用均值变化法和线性回归估计EORTC QLQ-C30组内及组间变化的最小重要差异(MID)。结果显示MID随量表、变化方向、锚和时间段而异,多数量表绝对值在5至10分之间,可用于解读评分变化及辅助黑色素瘤样本量计算。
要点
- EORTC QLQ-C30多数量表MID绝对值范围为5至10分。
- MID因量表、改善或恶化方向、锚及时间段不同而异。
- 结果有助于解读评分变化并优化辅助黑色素瘤样本量计算。
核心结论
- 恶性黑色素瘤患者EORTC QLQ-C30组内变化MID为改善4至18分、恶化-16至-4分,组间变化MID为3至16分和-16至-3分。
- 多数QLQ-C30量表MID绝对值范围为5至10分。
研究设计与样本
- 汇总三项已发表的黑色素瘤III期试验数据,评估从治疗开始至治疗结束及治疗结束至随访结束的HRQOL变化。
- 以临床医生评分(如体能状态)为锚,按相关强度和临床合理性选择锚与QLQ-C30量表配对。
- 形成恶化一个锚类别、改善一个锚类别和无变化三组,排除锚变化更大的患者。
主要发现
- MID随QLQ-C30量表、变化方向(改善对恶化)、锚和时间段而变化。
- 组内变化MID:改善4至18分,恶化-16至-4分。
- 组间变化MID:改善3至16分,恶化-16至-3分。
- 多数QLQ-C30量表MID绝对值在5至10分之间。
关键数值与推荐
- 组内变化MID范围为4至18分(改善)和-16至-4分(恶化)。
- 组间变化MID范围为3至16分(改善)和-16至-3分(恶化)。
- 多数QLQ-C30量表MID绝对值范围为5至10分。
临床怎么用
- 可用于解读恶性黑色素瘤患者EORTC QLQ-C30评分随时间的变化是否具有临床意义。
- 有助于在辅助黑色素瘤背景下进行更准确的样本量计算。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Health-related quality of life (HRQOL) is increasingly recognised as an important end-point in cancer clinical trials. The concept of minimally important difference (MID) enables interpreting differences and changes in HRQOL scores in terms of clinical meaningfulness. We aimed to estimate MIDs for interpreting group-level change of European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 (EORTC QLQ-C30) scores in patients with malignant melanoma. METHODS: Data were pooled from three published melanoma phase III trials. Anchors relying on clinician's ratings, e.g. performance status, were selected using correlation strength and clinical plausibility of associating the anchor/EORTC QLQ-C30 scale pair. HRQOL change was evaluated between time periods that were common to all trials: start of treatment to end of treatment and end of treatment to end of follow-up. Three change status groups were formed: deteriorated by one anchor category, improved by one anchor category and no change. Patients with greater anchor change were excluded. The mean change method and linear regression were used to estimate MIDs for change in HRQOL scores within the group and between the groups of patients, respectively. RESULTS: MIDs varied according to QLQ-C30 scale, direction (improvement versus deterioration), anchor and period. MIDs for within-group change ranged from 4 to 18 points (improvement) and -16 to -4 points (deterioration), and MIDs for between-group change ranged from 3 to 16 points and from -16 to -3 points. MIDs for most of QLQ-C30 scales ranged from 5 to 10 points in absolute values. CONCLUSIONS: These results are useful for interpreting changes in EORTC QLQ-C30 scores over time and for performing more accurate sample size calculations in adjuvant melanoma settings.
引用
- Musoro JZ, Bottomley A, Coens C, et al. Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma. Eur J Cancer. 2018. PMID: 30359910. doi:10.1016/j.ejca.2018.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。